Nafithromycin

India launches first indigenous antibiotic 'Nafithromycin' to combat drug-resistant pneumonia, offering 10x efficacy with a three-day treatment regimen. Developed with support from BIRAC, it targets Community-Acquired Bacterial Pneumonia and awaits CDSCO approval.

Union Minister Dr Jitendra Singh launched India's first indigenous antibiotic, Nafithromycin (Miqnaf), developed by Wockhardt with BIRAC support, targeting drug-resistant pneumonia, 10x more effective than azithromycin, with a 3-day regimen, awaiting CDSCO approval.

Dr Jitendra Singh announces soft launch of first indigenous antibiotic, Nafithromycin, to combat AMR.

India launches first indigenous antibiotic Nafithromycin, developed by Wockhardt with BIRAC support, targeting drug-resistant pneumonia. It is ten times more effective than existing options and offers a three-day treatment regimen, marking a significant step in India's fight against Antimicrobial Resistance (AMR).

Dr. Jitendra Singh announces the soft launch of India's first indigenous antibiotic, Nafithromycin, developed by Wockhardt with support from BIRAC. This new antibiotic, ten times more effective than current options, targets drug-resistant pneumonia with a three-day treatment regimen, addressing a global health crisis of antimicrobial resistance.

Indian drug regulator's Subject Expert Committee recommends Wockhardt's Miqnaf, a novel antibiotic for treating Community-Acquired Bacterial Pneumonia (CABP) in adults, based on comprehensive review of clinical studies. Miqnaf, a once-a-day, 3-day treatment, is effective against multi-drug resistant pathogens, potentially reducing hospitalization needs.

Wockhardt submitted phase-3 data for Nafithromycin 400 mg, a pneumonia treatment, to CDSCO. Approval expected within weeks, with launch in India by early 2024. India faces 18 million pneumonia cases annually, with domestic market potential of ₹400-500 crore in 3-5 years. Nafithromycin, an ultra-short-acting oral treatment with 97% success rate, also targets international markets, including Saudi Arabia.

Wockhardt receives favourable recommendation from CDSCO's SEC for its novel antibiotic Miqnaf, developed for treating community-acquired bacterial pneumonia (CABP) in adults. Miqnaf, a 3-day treatment, targets CABP, including cases caused by multi-drug resistant bugs. India contributes to 23% of the global CABP burden. Wockhardt shares rose 5% to Rs 994.95 on BSE.